3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Various Advanced Cancer
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Tertiary Lymphoid Structures
×
relatlimab
×
Clear all
NCT04095208
2026-04-21
CONGRATS
Institut Bergonié
Phase 2
Completed
68 enrolled